Key insights
- Eli Lilly significantly beat Q1 earnings and revenue estimates, driven by strong sales of Mounjaro and Zepbound. The company raised its 2026 revenue and EPS guidance. Lilly's dominance in the GLP-1 market, with a 60% share, signals continued growth in the obesity and diabetes treatment sector, positively influencing the healthcare sector and overall market sentiment.
Eli Lilly crushed Q1 and raised guidance again.
EPS: $8.55 vs $6.66 expected
Revenue: $19.8B vs $17.62B expected (+56% YoY)
Stock up 5% premarket
Main driver was GLP-1 demand: Mounjaro: $8.66B revenue (+125%), beat estimates
Zepbound: $4.16B US revenue (+80%), also beat Lilly now expects 2026 revenue of $82B–$85B (was $80B–$83B) and adjusted EPS of $35.50–$37 (was $33.50–$35). They currently hold about 60% of the US obesity/diabetes GLP-1 market, ahead of Novo at 39%.
Even with lower prices, demand keeps ripping. New obesity pill Foundayo just launched, so next earnings call will probably focus on whether it can become another monster product.